The 33% ORR and 7.4-month mPFS compare favorably to the 3-4 months typical for salvage chemotherapy alone, per management. Watch for regulatory alignment discussions and Phase 3 trial design details. The stock's 10.4% normal daily move means a 6 impact score implies a move of roughly 1.5-2.5 standard deviations.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 9 $12.68entry
- T+1 · 7d ago +1.89%α +2.26% · $12.92
- T+5 · 15h ago −26.81%α −25.12% · $9.28
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Faeth Therapeutics announced positive preliminary Phase 2 topline results for PIKTOR (serabelisib + sapanisertib) plus paclitaxel in advanced endometrial cancer. The trial met its primary endpoint with a 33% confirmed ORR and 7.4-month median PFS in a heavily pretreated population. The company plans to advance to a Phase 3 registrational trial, subject to regulatory alignment.
Key Facts
- Confirmed ORR of 33% (12 of 36 efficacy-evaluable patients) in advanced endometrioid endometrial cancer
- Among PIK3CA-mutation patients, confirmed ORR was 44% (7 of 16)
- Preliminary median PFS of 7.4 months (95% CI 5.3-NR) and 6-month PFS rate of 62%
- Disease control rate (DCR) of 83% (30 of 36)
- 5% discontinuation rate due to treatment-related adverse events; no treatment-related deaths
- Company plans to advance PIKTOR into a Phase 3 registrational trial
- Trial conducted in collaboration with GOG Foundation (GOG-3111)
Financial Impact
No financial figures disclosed; clinical data supports potential regulatory path for lead asset PIKTOR
Risk Factors
- Data are preliminary from a single-arm Phase 2 trial; results may change with further follow-up
- PIKTOR is investigational and not yet approved by any regulatory authority
- 64% of patients had grade 3 or higher treatment-related adverse events, notably neutropenia (26% grade 3+)
- Phase 3 trial design and regulatory alignment are not yet finalized
- Company may need additional financing to fund Phase 3 development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-452643 |
| Document: d199028d8k.htm | 0001193125-26-452643 |
| Document: 0001193125-26-452643-index-headers.html | 0001193125-26-452643 |
| Document: 0001193125-26-452643-index.html | 0001193125-26-452643 |
| Document: 0001193125-26-452643.txt | 0001193125-26-452643 |
Track record
12 reports on FTH
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry price pending
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $10.03 Now $9.28 −7.48% settles Nov 17
- Nov 9, 20267d ago 8-K Bullish 6/10 Entry $12.68 to $12.92 Now $9.28 −26.81% ▲ +1.89% +2.26% vs SPY
- Nov 9, 20267d ago 8-K Bullish 6/10 Viewing Entry $12.68 to $12.92 Now $9.28 −26.81% ▲ +1.89% +2.26% vs SPY
- Nov 3, 202613d ago 8-K Neutral 5/10 Entry $19.65 to $19.99 Now $9.28 −52.77% ▲ +1.73% +0.08% vs SPY
- Oct 27, 202620d ago 3 Neutral 2/10 Entry $19.20 to $18.75 Now $9.28 −51.67% ▼ −2.34% −1.96% vs SPY
- Oct 27, 202620d ago 8-K Neutral 2/10 Entry $19.11 to $19.20 Now $9.28 −51.44% ▲ +0.47% +0.13% vs SPY
- Sep 15, 20268w ago 3 Neutral 2/10 Entry $34.24 to $35.13 Now $9.28 −72.90% ▲ +2.60% +1.47% vs SPY
- Aug 11, 202613w ago 144 Bearish 5/10 Entry $30.00 to $29.38 Now $9.28 +69.07% ▲ +2.07% +2.32% vs SPY
- Aug 4, 202614w ago 8-K Neutral 3/10 Entry $25.50 to $24.59 Now $9.28 −63.61% ▼ −3.57% −3.37% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers